Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized tenecteplase dose in non-large-vessel ischemic stroke within 4.5 hours
ChiCTR2600124514Phase 4Not yet recruiting
- Sponsor
- Ganzhou People's Hospital
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Ganzhou People's Hospital. Primary endpoints: Proportion of patients with mRS 0–1 at 90 days and Incidence of symptomatic intracranial hemorrhage within 48 hours. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600124514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124514.